1 / 8

Cost-Effectiveness and Outcomes of Simvastatin Use in the Heart Protection Study

This analysis examines the outcomes and cost-effectiveness of 40 mg daily simvastatin in the Heart Protection Study (HPS) population. Key findings reveal observed and predicted differences in major adverse cardiovascular events (MACE) and deaths from vascular causes between placebo and simvastatin groups. The study predicts life years gained through full compliance with simvastatin, providing insight into long-term health benefits and costs per life year gained. These results underscore the value of simvastatin in improving health outcomes within the HPS framework.

efuru
Download Presentation

Cost-Effectiveness and Outcomes of Simvastatin Use in the Heart Protection Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Schematic of the state transition model Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  2. Observed and predicted difference in annual rates of MACE or deaths from vascular causes between groups allocated to placebo and simvastatin Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  3. Predicted life years gained (95% confidence interval) by full compliance with lifetime use of 40 mg simvastatin daily for the population of the HPS (not discounted) Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  4. Outcome measures with full compliance with lifetime use of generic 40 mg simvastatin daily for the HPS population Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  5. Additional scenarios of full compliance with 40 mg simvastatin daily within the population of the HPS Values are life years gained Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  6. Cost (£) per life year gained (unless stated otherwise) for various scenarios of full compliance with 40 mg simvastatin daily for the population of the HPS Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  7. Life years gained by full compliance with lifetime use of generic 40 mg simvastatin daily projected beyond the population of the HPS Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

  8. Cost effectiveness of full compliance with lifetime use of generic 40 mg simvastatin daily projected beyond the population of the HPS Heart Protection Study Collaborative Group BMJ; 2006;333:1145-

More Related